Maxcyte (MXCT) Cash from Operations (2020 - 2026)

Maxcyte has reported Cash from Operations over the past 6 years, most recently at 2689000.0 for Q4 2025.

  • Quarterly Cash from Operations rose 65.62% to 2689000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 34410000.0 through Dec 2025, down 24.63% year-over-year, with the annual reading at 34410000.0 for FY2025, 24.63% down from the prior year.
  • Cash from Operations was 2689000.0 for Q4 2025 at Maxcyte, up from 7458000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 981000.0 in Q4 2023 and troughed at 14411000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 4738050.0 (2021), against an average of 5458430.0.
  • Year-over-year, Cash from Operations skyrocketed 120.94% in 2022 and then crashed 1200.04% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 960250.0 in 2021, then tumbled by 533.83% to 6086400.0 in 2022, then soared by 116.12% to 981000.0 in 2023, then crashed by 897.25% to 7821000.0 in 2024, then skyrocketed by 65.62% to 2689000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Cash from Operations are 2689000.0 (Q4 2025), 7458000.0 (Q3 2025), and 9852000.0 (Q2 2025).